Cardium Therapeutics Inc Share Price Nyse
Equities
US1419161062
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Sales 2019 | - | Sales 2020 | - | Capitalization | 551K 46.02M |
---|---|---|---|---|---|
Net income 2019 | - 0 | Net income 2020 | - 0 | EV / Sales 2019 | - |
Net Debt 2019 | 1.12M 93.69M | Net Debt 2020 | 874K 73.08M | EV / Sales 2020 | - |
P/E ratio 2019 |
3.09
x | P/E ratio 2020 |
-1.77
x | Employees | - |
Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 93.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 22/03/22 | |
James Grainer
CHM | Chairman | 69 | 22/20/22 |
Lois Chandler
COO | Chief Operating Officer | - | 01/10/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 22/03/22 | |
James Grainer
CHM | Chairman | 69 | 22/20/22 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 22/20/22 |
1st Jan change | Capi. | |
---|---|---|
+49.41% | 56.95B | |
+39.98% | 40.26B | |
-7.19% | 39.32B | |
-4.42% | 28.37B | |
+12.31% | 26.45B | |
-18.21% | 19.41B | |
+29.54% | 12.54B | |
+25.99% | 12.21B | |
-0.82% | 12.15B |